MovDisordV3, PubMed, Curation, bibRecord, 003423

Cabergoline versus levodopa monotherapy.

Identifieur interne : 003423 ( PubMed/Curation ); précédent : 003422; suivant : 003424

Cabergoline versus levodopa monotherapy.

Auteurs : Keith Wheatley ; Carl E. Clarke ; Natalie Ives ; Richard Gray

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.

RBID : pubmed:15197724

English descriptors

KwdEn :
- Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Cost-Benefit Analysis, Ergolines (economics), Ergolines (therapeutic use), Humans, Levodopa (economics), Levodopa (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (economics).
MESH :
- chemical , economics : Antiparkinson Agents, Ergolines, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Ergolines, Levodopa.
- drug therapy : Parkinson Disease.
- economics : Parkinson Disease.
- Cost-Benefit Analysis, Humans, Middle Aged.

DOI: 10.1002/mds.20032
PubMed: 15197724

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003423

Links to Exploration step

pubmed:15197724

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cabergoline versus levodopa monotherapy.</title>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E" last="Clarke">Carl E. Clarke</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15197724</idno>
<idno type="pmid">15197724</idno>
<idno type="doi">10.1002/mds.20032</idno>
<idno type="wicri:Area/PubMed/Corpus">003423</idno>
<idno type="wicri:Area/PubMed/Curation">003423</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cabergoline versus levodopa monotherapy.</title>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E" last="Clarke">Carl E. Clarke</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cost-Benefit Analysis</term>
<term>Ergolines (economics)</term>
<term>Ergolines (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (economics)</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15197724</PMID>
<DateCreated><Year>2004</Year>
<Month>06</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted><Year>2004</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>19</Volume>
<Issue>6</Issue>
<PubDate><Year>2004</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cabergoline versus levodopa monotherapy.</ArticleTitle>
<Pagination><MedlinePgn>733-4; author reply 734-5</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wheatley</LastName>
<ForeName>Keith</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Clarke</LastName>
<ForeName>Carl E</ForeName>
<Initials>CE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ives</LastName>
<ForeName>Natalie</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gray</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>LL60K9J05T</RegistryNumber>
<NameOfSubstance UI="C047047">cabergoline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Mov Disord. 2003 Aug;18(8):898-905</RefSource>
<PMID Version="1">12889079</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003362">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004873">Ergolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>6</Month>
<Day>16</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>10</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>6</Month>
<Day>16</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15197724</ArticleId>
<ArticleId IdType="doi">10.1002/mds.20032</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003423 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003423 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15197724
   |texte=   Cabergoline versus levodopa monotherapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:15197724" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Cabergoline versus levodopa monotherapy.

Cabergoline versus levodopa monotherapy.

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki